SCHEMBL1679787

SCHEMBL1679787

CC(CCCCC(N)=O)C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.48
CA1 P00915 3/20 0.40
DPP4 P27487 1/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
KDM4E B2RXH2 2/20 0.38
SOAT1 P35610 2/20 0.38
KMT2A Q03164 2/20 0.38
ALOX15 P16050 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
CYP1A2 P05177 2/20 0.38
MEN1 O00255 1/20 0.38
FAAH O00519 1/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
FFAR4 Q5NUL3 1/20 0.36
FFAR1 O14842 1/20 0.36
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15156195 0.98 LTA4H (0.47) LTA4HCA1DPP4DPP8DPP9
SCHEMBL28107169 0.98 LTA4H (0.47) LTA4HCA1DPP4DPP8DPP9
SCHEMBL2904041 0.98 LTA4H (0.47) LTA4HCA1DPP4DPP8DPP9
SCHEMBL11137912 0.93 LTA4H (0.41) LTA4HCA1DPP4DPP8DPP9
SCHEMBL9763558 0.87 CA1 (0.44) LTA4HCA1BLMFFAR4FFAR1
SCHEMBL29150389 0.86 FFAR4 (0.52) LTA4HPMP22CYP1A2FFAR4FFAR1
SCHEMBL14895150 0.85 ALOX15 (0.46) LTA4HCA1DPP4DPP8DPP9
SCHEMBL487784 0.85 ALOX15 (0.46) LTA4HCA1DPP4DPP8DPP9
SCHEMBL5816226 0.85 CA1 (0.43) LTA4HCA1BLMFFAR4FFAR1
SCHEMBL15774679 0.85 ALOX15 (0.46) LTA4HCA1DPP4DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1448607-A1 COMPOSITION AND METHOD TO HOMOGENEOUSLY MODIFY OR CROSS-LINK CHITOSAN UNDER NEUTRAL CONDITIONS Biosyntech Canada Inc. (CA) 2004-08-25 EP claimed
WO-2003042250-A1 COMPOSITION AND METHOD TO HOMOGENEOUSLY MODIFY OR CROSS-LINK CHITOSAN UNDER NEUTRAL CONDITIONS BIOSYNTECH CANADA INC. (CA) 2003-05-22 WO claimed
CN-112105360-B BCL-2 protein degrading agent for cancer treatment 生物风险投资有限责任公司 2024-01-30 CN disclosed
CN-112105360-A BCL-2 protein degrading agents for cancer treatment 生物风险投资有限责任公司 2020-12-18 CN disclosed
EP-2502903-A1 PROCESS FOR PRODUCING 3-ALKOXY-2-AMINO-6-FLUOROBICYCLO[3.1.0]HEXANE-2,6-DICARBOXYLIC ACID DERIVATIVE AND INTERMEDIATE THEREOF Taisho Pharmaceutical Co., Ltd. (JP) 2012-09-26 EP disclosed
EP-2303920-A2 AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES Abbott Laboratories (US) 2011-04-06 EP disclosed
WO-2010011947-A2 AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES ABBOTT LABORATORIES (US) 2010-01-28 WO disclosed
US-5310880-A Chromatography, alkali halide, acid solution THE GENERAL HOSPITAL CORPORATION (US) 1994-05-10 US disclosed
WO-1992018145-A1 PURIFICATION OF MÜLLERIAN INHIBITING SUBSTANCE THE GENERAL HOSPITAL CORPORATION (US) 1992-10-29 WO disclosed